Comparative effectiveness of bevacizumab, cetuximab, and panitumumab for improving outcomes in metastatic colorectal cancer: a propensity overlap weighting analysis.

ABSTRACT:

Purpose

Metastatic colorectal cancer (mCRC) remains a leading cause of cancer-related mortality despite advancements in targeted therapies. Monoclonal antibody medications-namely, bevacizumab, cetuximab, and panitumumab-are widely used in combination with chemotherapy as first-line treatments for unresectable mCRC in patients harboring wild-type KRAS tumors. However, the comparative effectiveness of these treatments in improving survival outcomes has not been clearly evaluated. This study aimed to directly compare the effectiveness of these 3 targeted therapies on survival outcomes in patients with unresectable mCRC.

Methods

In this retrospective cohort study, we utilized Taiwan's National Health Insurance Database and Taiwan Cancer Registry to identify patients newly diagno

SUBMITTER: Su YC 

PROVIDER: S-EPMC12569773 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature